Damora Therapeutics Inc (DMRA)

Currency in USD
25.780
+0.120(+0.47%)
Real-time Data·
DMRA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
25.27026.293
52 wk Range
2.45038.325
Key Statistics
Prev. Close
25.66
Open
25.5
Day's Range
25.27-26.293
52 wk Range
2.45-38.325
Volume
148.92K
Average Volume (3m)
301.4K
1-Year Change
759.3333%
Book Value / Share
-110.1
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DMRA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
45.167
Upside
+75.20%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Damora Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 45.167
(+75.20% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
RBC Capital
Buy40.00+55.40%-New Coverage23-04-2026
Evercore ISI
Buy46.00+78.71%-New Coverage25-03-2026
Guggenheim
Buy40.00+55.40%36.00Maintain17-02-2026
UBS
Buy45.00+74.83%-New Coverage17-02-2026
LifeSci Capital
Buy40.00+55.40%-New Coverage02-02-2026

Earnings

Latest Release
19-03-2026
EPS / Forecast
-135.60 / -0.13
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

DMRA Income Statement

Compare DMRA to Peers and Sector

Metrics to compare
DMRA
Peers
Sector
Relationship
P/E Ratio
−7.3x−4.5x−0.5x
PEG Ratio
0.01−0.010.00
Price/Book
−8.7x2.3x2.6x
Price / LTM Sales
-2.2x3.2x
Upside (Analyst Target)
75.4%207.6%48.8%
Fair Value Upside
Unlock18.5%6.9%Unlock

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
787.90K1.31%20.22M
Other Institutional Investors
25.78M42.75%661.55M
Public Companies & Retail Investors
33.73M55.94%865.61M
Total
60.3M100.00%1.55B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Fidelity Mt. Vernon Street Trust - Fidelity Growth Company Fund2.92%17,58,67445,128
Fidelity Mt. Vernon Street Trust - Fidelity Growth Company K6 Fund0.87%5,21,92213,393

FAQ

What Is the Damora Therapeutics (DMRA) Share Price Today?

The Damora Therapeutics share price today is 25.780.

What is the current Damora Therapeutics (DMRA) share price and day range?

As of 01-05-2026, the Damora Therapeutics share price is 25.780, with a previous close of 25.660. The share price has ranged from 25.270 to 26.293 today, while the 52-week range spans from 2.450 to 38.325.

What Is the Damora Therapeutics Market Cap?

As of today, Damora Therapeutics market cap is 1.530B.

What Is the Damora Therapeutics (DMRA) Share Price Target?

The average 12-month share price target for Damora Therapeutics is 45.167, with a high estimate of 55 and a low estimate of 40. 6 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +75.20% Upside potential.

What Is Damora Therapeutics's Earnings Per Share (TTM)?

The Damora Therapeutics EPS (TTM) is -153.953.

From a Technical Analysis Perspective, Is DMRA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

What Stock Exchange Does Damora Therapeutics Trade On?

Damora Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Damora Therapeutics?

The stock symbol for Damora Therapeutics is "DMRA."

How Many Times Has Damora Therapeutics Stock Split?

Damora Therapeutics has split 1 times.

How Many Employees Does Damora Therapeutics Have?

Damora Therapeutics has 7 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.